RecruitingPhase 2NCT06850623
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
A Phase 2 Study to Investigate the Efficacy and Safety of Acoustic Cluster Therapy With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer
Sponsor
EXACT Therapeutics AS
Enrollment
25 participants
Start Date
Jun 19, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Not deemed suitable for primary curative surgery and have radiographic and pathological disease consistent with inoperable LAPC or borderline resectable pancreatic cancer.
- Suitable to receive treatment with mFOLFIRINOX according to the Investigator's assessment.
Exclusion Criteria1
- • Any prior anti-cancer treatment for pancreatic cancer (e.g. chemotherapy, surgery, radiation). Palliative bypass procedure and bile duct stenting are allowed.
Interventions
COMBINATION_PRODUCTAcoustic Cluster Therapy
Drug: PS101; Device: Ultrasound
DRUGModified FOLFIRINOX
Chemotherapy
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06850623
Related Trials
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT0417253244 locations
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT066730176 locations
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT06998940196 locations
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
NCT071570332 locations
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
NCT068610883 locations